title: Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience.
abstract: Relapsed or refractory Hodgkin lymphoma (advanced HL) still remains a therapeutic challenge. Recently, unmanipulated haploidentical related donor transplant with reduced conditioning regimen (HAPLO-RIC) and post-transplant cyclophosphamide (PT-Cy) as GvHD prophylaxis has became a promising rescue strategy potentially available to almost every patient. This paper reports our multicenter experience using an IV busulfan-based HAPLO-RIC regimen and PT-Cy in the treatment of 43 patients with advanced HL. Engraftment occurred in 42 patients (97.5%), with a median time to neutrophil and platelet recovery of 18 and 26 days. Cumulative incidences of grades II-IV acute GvHD and chronic GvHD were 39% and 19%, respectively. With a median follow-up of 25.5 months for survivors, 27 patients are alive, with 22 of them disease free. Cumulative incidences of 1-year non-relapse mortality and relapse at 2 years were 21% and 24%, respectively. The estimated 2-year event-free survival (EFS) and overall survival (OS) were 48% and 58%, respectively. CR prior to HAPLO-RIC correlated with better EFS (78.5% vs 33.5%; P=0.015) and OS (86% vs 46%; P=0.044). Our findings further confirm prior reports using HAPLO-RIC in advanced HL in a multicenter approach employing an IV busulfan-based conditioning regimen.
authors.affiliation: Servicio de Hematología, Unidad de Trasplante Hematopoyético, HGU Gregorio Marañón, Madrid, Spain.|Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
authors.forename: J
authors.identifier: http://orcid.org/0000-0002-6057-6672
authors.initials: J
authors.lastname: Gayoso
authors.affiliation: Servicio de Hematología, Unidad de Trasplante Hematopoyético, HGU Gregorio Marañón, Madrid, Spain.|Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
authors.forename: P
authors.initials: P
authors.lastname: Balsalobre
authors.affiliation: Hospital Regional Universitario, Málaga, Spain.
authors.forename: M J
authors.initials: MJ
authors.lastname: Pascual
authors.affiliation: HGU Morales Meseguer, Murcia, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Castilla-Llorente
authors.affiliation: Hospital Clínico Universitario, Salamanca, Spain.
authors.forename: L
authors.initials: L
authors.lastname: López-Corral
authors.affiliation: Servicio de Hematología, Unidad de Trasplante Hematopoyético, HGU Gregorio Marañón, Madrid, Spain.|Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Kwon
authors.affiliation: Servicio de Hematología, Unidad de Trasplante Hematopoyético, HGU Gregorio Marañón, Madrid, Spain.|Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
authors.forename: D
authors.initials: D
authors.lastname: Serrano
authors.affiliation: Hospital Clínico Universitario, Valencia, Spain.
authors.forename: J L
authors.initials: JL
authors.lastname: Piñana
authors.affiliation: Hospital Universitario Ramón y Cajal, Madrid, Spain.
authors.forename: P
authors.initials: P
authors.lastname: Herrera
authors.affiliation: ICO Badalona, Badalona, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Ferrá
authors.affiliation: Servicio de Hematología, Unidad de Trasplante Hematopoyético, HGU Gregorio Marañón, Madrid, Spain.|Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Pascual
authors.affiliation: HGU Morales Meseguer, Murcia, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Heras
authors.affiliation: Hospital Universitario La Fé, Valencia, Spain.
authors.forename: P
authors.identifier: http://orcid.org/0000-0002-3275-5593
authors.initials: P
authors.lastname: Montesinos
authors.affiliation: Complejo Hospitalario de Navarra, Pamplona, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Zabalza
authors.affiliation: Hospital Universitario Son Espases, Palma de Mallorca, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Bento
authors.affiliation: Hospital Universitario La Princesa, Madrid, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Figuera
authors.affiliation: Servicio de Hematología, Unidad de Trasplante Hematopoyético, HGU Gregorio Marañón, Madrid, Spain.|Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Buño
authors.affiliation: Servicio de Hematología, Unidad de Trasplante Hematopoyético, HGU Gregorio Marañón, Madrid, Spain.|Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
authors.forename: J L
authors.initials: JL
authors.lastname: Díez-Martín
mesh_terms: D000293:Adolescent; D000328:Adult; D002066:Busulfan / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D006689:Hodgkin Disease / Q000150:complications / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016879:Salvage Therapy / Q000379:methods / Q000401:mortality; D013030:Spain; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000379:methods*; D000075442:Transplantation, Haploidentical / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D055815:Young Adult
chemical_list: D003520:Cyclophosphamide; D002066:Busulfan